114 related articles for article (PubMed ID: 38436113)
1. Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors.
El-Zoghbi MS; Bass AK; A Abuo-Rahma GE; Mohamed MF; Badr M; Al-Ghulikah HA; Abdelhafez EM
Future Med Chem; 2024 Apr; 16(7):601-622. PubMed ID: 38436113
[No Abstract] [Full Text] [Related]
2. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
3. Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.
Mourad AAE; Mourad MAE; Jones PG
Drug Des Devel Ther; 2020; 14():3111-3130. PubMed ID: 32848361
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
[TBL] [Abstract][Full Text] [Related]
5. Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity.
Tang H; Liang Y; Yu M; Cai S; Ding K; Wang Y
Bioorg Med Chem; 2023 Sep; 92():117437. PubMed ID: 37563016
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
7. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function.
Schmitt F; Gosch LC; Dittmer A; Rothemund M; Mueller T; Schobert R; Biersack B; Volkamer A; Höpfner M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658435
[TBL] [Abstract][Full Text] [Related]
8. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma.
Tang H; Liang Y; Shen H; Cai S; Yu M; Fan H; Ding K; Wang Y
Bioorg Chem; 2022 Nov; 128():106112. PubMed ID: 36070628
[TBL] [Abstract][Full Text] [Related]
10. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
12. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Lee HY; Lee JF; Kumar S; Wu YW; HuangFu WC; Lai MJ; Li YH; Huang HL; Kuo FC; Hsiao CJ; Cheng CC; Yang CR; Liou JP
Eur J Med Chem; 2017 Jan; 125():1268-1278. PubMed ID: 27886544
[TBL] [Abstract][Full Text] [Related]
13. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
14. 2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition.
Romagnoli R; Kimatrai Salvador M; Schiaffino Ortega S; Baraldi PG; Oliva P; Baraldi S; Lopez-Cara LC; Brancale A; Ferla S; Hamel E; Balzarini J; Liekens S; Mattiuzzo E; Basso G; Viola G
Eur J Med Chem; 2018 Jan; 143():683-698. PubMed ID: 29220790
[TBL] [Abstract][Full Text] [Related]
15. A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo.
Li YR; Liu FF; Liu WB; Zhang YF; Tian XY; Fu XJ; Xu Y; Song J; Zhang SY
Biochem Pharmacol; 2022 Jul; 201():115070. PubMed ID: 35526597
[TBL] [Abstract][Full Text] [Related]
16. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer.
Xie S; Leng J; Zhao S; Zhu L; Zhang M; Ning M; Zhao B; Kong L; Yin Y
Eur J Med Chem; 2024 Mar; 268():116301. PubMed ID: 38452727
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
Zhu H; Tan Y; He C; Liu Y; Duan Y; Zhu W; Zheng T; Li D; Xu J; Yang DH; Chen ZS; Xu S
J Med Chem; 2022 Aug; 65(16):11187-11213. PubMed ID: 35926141
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors.
Chi Z; Bai Y; Li J; Wang K; Xu Y; Luan Y
Bioorg Med Chem Lett; 2022 Sep; 71():128821. PubMed ID: 35643262
[TBL] [Abstract][Full Text] [Related]
20. A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics.
Al-Hamashi AA; Koranne R; Dlamini S; Alqahtani A; Karaj E; Rashid MS; Knoff JR; Dunworth M; Pflum MKH; Casero RA; Perera L; Taylor WR; Tillekeratne LMV
Bioorg Chem; 2021 Nov; 116():105297. PubMed ID: 34509798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
